Madrigal Pharmaceuticals Inc. | Mid-cap | Healthcare
$414.68
1.86%
| Madrigal Stock Comparison:
Madrigal vs VertexMadrigal vs RegeneronMadrigal vs BridgeBio PharmaMadrigal vs Blueprint MedicinesMadrigal vs HalozymeMadrigal vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 137.2M
Gross Profit 132.7M 96.71%
Operating Income -79.3M -57.79%
Net Income -73.2M -53.36%
EPS (Diluted) $-3.32

Balance Sheet Metrics

Total Assets 996.6M
Total Liabilities 286.0M
Shareholders Equity 710.6M
Debt to Equity 0.40

Cash Flow Metrics

Operating Cash Flow -81.8M
Free Cash Flow -88.9M

Revenue & Profitability Trend

Madrigal Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i180.1M0000
Cost of Goods Sold i6.2M----
Gross Profit i173.9M----
Gross Margin % i96.5%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i236.7M272.4M245.4M205.2M184.8M
Selling, General & Administrative i435.1M108.1M48.1M37.3M21.9M
Other Operating Expenses i-----
Total Operating Expenses i671.8M380.5M293.6M242.5M206.7M
Operating Income i-497.9M-380.5M-293.6M-242.5M-206.7M
Operating Margin % i-276.4%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i46.7M19.6M2.2M363.0K4.3M
Interest Expense i14.7M12.7M4.0M0-
Other Non-Operating Income---273.0K100.0K
Pre-tax Income i-465.9M-373.6M-295.4M-241.8M-202.2M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-465.9M-373.6M-295.4M-241.8M-202.2M
Net Margin % i-258.6%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-450.1M-360.4M-290.9M-241.4M-206.2M
EPS (Basic) i$-21.90$-19.99$-17.23$-14.63$-13.09
EPS (Diluted) i$-21.90$-19.99$-17.23$-14.63$-13.09
Basic Shares Outstanding i2127296218687774171372011653518815446638
Diluted Shares Outstanding i2127296218687774171372011653518815446638

Income Statement Trend

Madrigal Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i100.0M99.9M331.5M36.3M54.0M
Short-term Investments i826.2M534.2M27.2M234.1M230.1M
Accounts Receivable i53.8M----
Inventory i34.1M----
Other Current Assets13.8M3.2M2.6M1.3M1.0M
Total Current Assets i1.0B637.3M361.4M271.7M285.2M
Non-Current Assets
Property, Plant & Equipment i4.6M3.3M1.2M1.6M1.8M
Goodwill i4.7M----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets-----
Total Non-Current Assets i9.3M3.3M1.2M1.6M1.8M
Total Assets i1.0B640.5M362.6M273.3M287.0M
Liabilities
Current Liabilities
Accounts Payable i43.6M28.0M23.8M21.4M1.0M
Short-term Debt i983.0K527.0K602.0K410.0K318.0K
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i169.3M118.5M115.9M76.8M46.6M
Non-Current Liabilities
Long-term Debt i118.6M116.7M49.3M387.0K468.0K
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i118.6M116.7M49.3M387.0K468.0K
Total Liabilities i287.9M235.2M165.2M77.2M47.0M
Equity
Common Stock i2.0K2.0K2.0K2.0K2.0K
Retained Earnings i-1.8B-1.3B-962.7M-667.3M-425.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i754.4M405.3M197.4M196.1M240.0M
Key Metrics
Total Debt i119.6M117.2M49.9M797.0K786.0K
Working Capital i863.6M518.7M245.5M194.8M238.6M

Balance Sheet Composition

Madrigal Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-465.9M-373.6M-295.4M-241.8M-202.2M
Depreciation & Amortization i1.1M527.0K467.0K405.0K471.0K
Stock-Based Compensation i79.9M49.7M31.6M26.9M20.7M
Working Capital Changes i-72.3M4.2M2.5M20.4M-161.0K
Operating Cash Flow i-455.6M-316.7M-260.0M-194.2M-181.2M
Investing Activities
Capital Expenditures i-1.5M-1.5M-217.0K-209.0K-334.0K
Acquisitions i-----
Investment Purchases i-1.1B-834.4M-143.5M-394.1M-329.3M
Investment Sales i863.3M333.4M350.4M389.3M489.5M
Investing Cash Flow i-269.4M-502.5M206.7M-5.1M159.8M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i065.0M50.0M0-
Debt Repayment i-----
Financing Cash Flow i397.5M324.8M304.5M170.2M4.4M
Free Cash Flow i-462.0M-325.7M-225.1M-184.1M-157.9M
Net Change in Cash i-327.5M-494.4M251.2M-29.1M-17.0M

Cash Flow Trend

Madrigal Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -18.94
Forward P/E -29.16
Price to Book 13.00
Price to Sales 17.60
PEG Ratio 0.26

Profitability Ratios

Profit Margin -54.68%
Operating Margin -22.18%
Return on Equity -36.30%
Return on Assets -18.31%

Financial Health

Current Ratio 5.11
Debt to Equity 17.81
Beta -1.03

Per Share Data

EPS (TTM) $-12.66
Book Value per Share $31.32
Revenue per Share $23.44

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
mdgl9.1B-18.9413.00-36.30%-54.68%17.81
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 63.6B15.122.0915.34%31.37%9.04
BridgeBio Pharma 9.6B-17.12-5.2836.76%98.25%-1.04
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50
Halozyme 8.4B16.3925.31179.14%47.28%462.23

Financial data is updated regularly. All figures are in the company's reporting currency.